Toll-like receptor 9 enhancement of antiviral immunity in chronic HIV-1 infection: a phase 1b/2a trial (TEACH)

Trial Profile

Toll-like receptor 9 enhancement of antiviral immunity in chronic HIV-1 infection: a phase 1b/2a trial (TEACH)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Lefitolimod (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms TEACH
  • Most Recent Events

    • 09 Aug 2017 Detailed results of the extension phase will be presented at an international scientific conference, according to a Mologen media release.
    • 09 Aug 2017 Results from the extension phase of this trial published in a Mologen media release.
    • 28 Jun 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top